MA55593A - Cycles pyridine contenant des dérivés servant d'inhibiteurs de malt1 - Google Patents
Cycles pyridine contenant des dérivés servant d'inhibiteurs de malt1Info
- Publication number
- MA55593A MA55593A MA055593A MA55593A MA55593A MA 55593 A MA55593 A MA 55593A MA 055593 A MA055593 A MA 055593A MA 55593 A MA55593 A MA 55593A MA 55593 A MA55593 A MA 55593A
- Authority
- MA
- Morocco
- Prior art keywords
- containing derivatives
- cycles containing
- derivatives serving
- malt1 inhibitors
- pyridine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962832608P | 2019-04-11 | 2019-04-11 | |
| EP19178959 | 2019-06-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA55593A true MA55593A (fr) | 2022-02-16 |
Family
ID=70224393
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA055593A MA55593A (fr) | 2019-04-11 | 2020-04-10 | Cycles pyridine contenant des dérivés servant d'inhibiteurs de malt1 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12404260B2 (fr) |
| EP (1) | EP3953345B1 (fr) |
| JP (1) | JP7554768B2 (fr) |
| KR (1) | KR20210151880A (fr) |
| CN (1) | CN113677674B (fr) |
| AU (1) | AU2020272156A1 (fr) |
| BR (1) | BR112021019799A2 (fr) |
| ES (1) | ES2949871T3 (fr) |
| MA (1) | MA55593A (fr) |
| MX (1) | MX2021012417A (fr) |
| WO (1) | WO2020208222A1 (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI795381B (zh) | 2016-12-21 | 2023-03-11 | 比利時商健生藥品公司 | 作為ｍａｌｔ１抑制劑之吡唑衍生物 |
| EP3953345B1 (fr) | 2019-04-11 | 2023-04-05 | Janssen Pharmaceutica NV | Dérivés de pyridines comme inhibiteurs de malt1 |
| WO2022101676A1 (fr) * | 2020-11-12 | 2022-05-19 | Monopteros Therapeutics,Inc. | Matériaux et procédés de traitement du cancer |
| CN118451068A (zh) | 2021-12-30 | 2024-08-06 | 上海翰森生物医药科技有限公司 | 三并环类衍生物抑制剂、其制备方法和应用 |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6339099B1 (en) | 1997-06-20 | 2002-01-15 | Dupont Pharmaceuticals Company | Guanidine mimics as factor Xa inhibitors |
| DK173431B1 (da) | 1998-03-20 | 2000-10-23 | Gea Farmaceutisk Fabrik As | Farmaceutisk formulering omfattende en 2-[[(2-pyridinyl)methyl]sulfinyl]benzimidazol med anti-ulcusaktivitet samt fremgangs |
| FR2795726A1 (fr) | 1999-06-30 | 2001-01-05 | Aventis Cropscience Sa | Nouveaux pyrazoles fongicides |
| GB9925127D0 (en) | 1999-10-22 | 1999-12-22 | Pharmacia & Upjohn Spa | Oral formulations for anti-tumor compounds |
| WO2003037274A2 (fr) | 2001-11-01 | 2003-05-08 | Icagen, Inc. | Pyrazole-amides et -sulfonamides |
| WO2004098515A2 (fr) | 2003-04-30 | 2004-11-18 | Agensys, Inc. | Acides nucleiques et proteines correspondantes appelees 109p1d4 utiles dans le traitement et la detection du cancer |
| EP2385041B1 (fr) | 2003-05-01 | 2013-09-18 | Bristol-Myers Squibb Company | Composés de pyrazole-amines utilés en tant qu'inhibiteurs de kinase |
| EP1847531A4 (fr) | 2005-02-09 | 2009-04-22 | Takeda Pharmaceutical | Derive de pyrazole |
| JP2009533327A (ja) | 2006-03-22 | 2009-09-17 | バーテックス ファーマシューティカルズ インコーポレイテッド | 増殖性疾患を処置するためのｃ−ＭＥＴキナーゼ阻害剤 |
| US20090253673A1 (en) | 2006-07-12 | 2009-10-08 | Min Ge | Substituted Pyrazoles as Ghrelin Receptor Antagonists |
| CN101583601B (zh) | 2007-01-17 | 2013-06-05 | 香港科技大学 | 作为褪黑素受体mt1和mt2的亚型选择性激动剂的异喹诺酮化合物 |
| WO2008110196A1 (fr) | 2007-03-09 | 2008-09-18 | High Point Pharmaceuticals, Llc | Indole- et benzimidazole amides comme inhibiteurs des hydroxystéroïde déshydrogénases |
| US8309523B2 (en) | 2007-11-21 | 2012-11-13 | Vib Vzw | Inhibitors of MALT1 proteolytic activity and uses thereof |
| RU2010153656A (ru) * | 2008-06-04 | 2012-07-20 | Амбрилиа Байофарма Инк. (Ca) | Ингибиторы интегразы вич из пиридоксина |
| KR101364869B1 (ko) | 2008-09-24 | 2014-02-21 | 바스프 에스이 | 무척추 해충을 방제하기 위한 피라졸 화합물 |
| WO2010039039A1 (fr) | 2008-10-03 | 2010-04-08 | Clavis Pharma Asa | Formulations orales de dérivés de gemcitabine |
| KR101061599B1 (ko) | 2008-12-05 | 2011-09-02 | 한국과학기술연구원 | 비정상 세포 성장 질환의 치료를 위한 단백질 키나아제 저해제인 신규 인다졸 유도체, 이의 약학적으로 허용가능한염 및 이를 유효성분으로 함유하는 약학적 조성물 |
| DE102009003954A1 (de) | 2009-01-07 | 2010-07-08 | Merck Patent Gmbh | Pyridazinonderivate |
| US8252821B2 (en) | 2009-04-14 | 2012-08-28 | Bristol-Myers Squibb Company | Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound |
| WO2011036885A1 (fr) | 2009-09-25 | 2011-03-31 | 武田薬品工業株式会社 | Composé hétérocyclique |
| US20120071497A1 (en) | 2010-06-03 | 2012-03-22 | Pharmacyclics, Inc. | Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase |
| CA3007787C (fr) | 2010-06-03 | 2020-03-10 | Pharmacyclics Llc | Utilisation d'inhibiteurs de la tyrosine kinase de bruton (btk) |
| ES2539379T3 (es) | 2010-06-22 | 2015-06-30 | Basf Se | Procedimiento de preparación de 4-hidroxipiridinas |
| US20130109682A1 (en) | 2010-07-06 | 2013-05-02 | Novartis Ag | Cyclic ether compounds useful as kinase inhibitors |
| TW201236685A (en) | 2010-11-11 | 2012-09-16 | Daiichi Sankyo Co Ltd | New pyrazole amide derivatives |
| JP6231085B2 (ja) | 2012-05-31 | 2017-11-15 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | アミノキナゾリン誘導体及びピリドピリミジン誘導体 |
| US20150225373A1 (en) | 2012-08-29 | 2015-08-13 | Respivert Limited | Kinase inhibitors |
| EA201590916A1 (ru) | 2012-11-09 | 2016-02-29 | Корнэлл Юниверсити | Низкомолекулярные ингибиторы malt1 |
| WO2014086478A1 (fr) | 2012-12-03 | 2014-06-12 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Inhibiteurs de la protéase malt1 |
| AR094412A1 (es) | 2013-01-10 | 2015-07-29 | Gruenenthal Gmbh | Carboxamidas basadas en pirazolilo i |
| SG11201607895PA (en) | 2014-05-28 | 2016-12-29 | Novartis Ag | Novel pyrazolo pyrimidine derivatives and their use as malt1 inhibitors |
| US20150361504A1 (en) | 2014-06-13 | 2015-12-17 | Pharmacyclics Llc | Biomarker for predicting response of cll to treatment with a btk inhibitor |
| WO2016005994A2 (fr) | 2014-07-06 | 2016-01-14 | Gattefosse India Pvt. Ltd. | Composition pharmaceutique comprenant une dispersion solide de médicaments de classe ii bcs avec gelucires |
| AU2015300966A1 (en) | 2014-08-08 | 2017-02-16 | Janssen Pharmaceutica Nv | Bruton's tyrosine kinase inhibitor combinations and uses thereof |
| WO2016037578A1 (fr) | 2014-09-10 | 2016-03-17 | Glaxosmithkline Intellectual Property Development Limited | Nouveaux composés utilisés comme inhibiteurs de la kinase réarrangée au cours de la transfection (ret) |
| HK1244427A1 (zh) | 2014-12-06 | 2018-08-10 | Intra-Cellular Therapies, Inc. | 有机化合物 |
| WO2016209688A1 (fr) | 2015-06-24 | 2016-12-29 | University Of Florida Research Foundation, Incorporated | Compositions destinées au traitement du cancer, et leurs utilisations |
| PT3371190T (pt) * | 2015-11-06 | 2022-07-08 | Incyte Corp | Compostos heterocíclicos como inibidores de pi3k-gamma |
| AU2016352813B2 (en) * | 2015-11-13 | 2019-09-19 | Novartis Ag | Novel pyrazolo pyrimidine derivatives |
| JO3794B1 (ar) | 2015-12-10 | 2021-01-31 | Janssen Pharmaceutica Nv | المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون |
| CN107021963A (zh) | 2016-01-29 | 2017-08-08 | 北京诺诚健华医药科技有限公司 | 吡唑稠环类衍生物、其制备方法及其在治疗癌症、炎症和免疫性疾病上的应用 |
| US10882841B2 (en) | 2016-03-01 | 2021-01-05 | University Of Maryland, Baltimore | Wnt signaling pathway inhibitors for treatments of disease |
| PE20190656A1 (es) * | 2016-07-29 | 2019-05-08 | Lupin Ltd | Compuestos de tiazolo-piridina sustituida como inhibidores de malt1 |
| WO2018103060A1 (fr) | 2016-12-09 | 2018-06-14 | Janssen Pharmaceutica Nv | Inhibiteurs de tyrosine kinase de bruton et leurs procédés d'utilisation |
| AU2017383236B2 (en) | 2016-12-21 | 2022-02-10 | Acerta Pharma B.V. | Imidazopyrazine inhibitors of Bruton's tyrosine kinase |
| JOP20190148A1 (ar) | 2016-12-21 | 2019-06-18 | Bayer Pharma AG | أشكال جرعات صيدلية تحتوي على مثبطات قنوات task-1 و task-3 واستخدامها لمعالجة الاضطرابات التنفسية |
| TWI795381B (zh) | 2016-12-21 | 2023-03-11 | 比利時商健生藥品公司 | 作為ｍａｌｔ１抑制劑之吡唑衍生物 |
| JOP20190152A1 (ar) | 2016-12-21 | 2019-06-20 | Novartis Ag | مضادات الميوستاتين، الآكتيفين أو مستقبلات الآكتيفين للاستخدام في علاج السمنة والحالات ذات الصلة |
| JOP20190141A1 (ar) | 2016-12-21 | 2019-06-12 | Bayer Pharma AG | أشكال جرعات صيدلية تحتوي على مثبطات لقناة task-1 و task-3 واستخدامها في معالجة اضطراب تنفسي |
| MX2019007161A (es) | 2016-12-21 | 2020-02-12 | Mereo Biopharma 3 Ltd | Uso de anticuerpos anti-esclerostina en el tratamiento de osteogenesis imperfecta. |
| US20200009135A1 (en) | 2017-02-01 | 2020-01-09 | Medivir Ab | Therapeutic applications of malt1 inhibitors |
| WO2018165385A1 (fr) | 2017-03-08 | 2018-09-13 | Cornell University | Inhibiteurs de malt1 et leurs utilisations |
| WO2018226150A1 (fr) | 2017-06-05 | 2018-12-13 | Medivir Aktiebolag | Pyrazolopyrimidine utilisés en tant qu'inhibiteurs de malt-1 |
| AU2018395291A1 (en) | 2017-12-28 | 2020-07-30 | The General Hospital Corporation | Targeting the CBM signalosome complex induces regulatory T cells to inflame the tumor microenvironment |
| EP3756268A1 (fr) | 2018-02-23 | 2020-12-30 | Industrieanlagen-Betriebsgesellschaft mbH | Dispositif de génération d'un champ magnétique, notamment pour un système de charge inductif, et dispositif primaire d'un système de charge inductif pour la charge dynamique de véhicules |
| AU2019289222B2 (en) * | 2018-06-18 | 2023-07-13 | Janssen Pharmaceutica Nv | Pyrazole derivatives as MALT1 inhibitors |
| EP3810609B1 (fr) * | 2018-06-18 | 2024-06-12 | Janssen Pharmaceutica NV | Dérivés de la pyrazole comme inhibiteurs de la malt1 |
| US20220175760A1 (en) | 2019-02-22 | 2022-06-09 | Janssen Pharmaceutica Nv | Pharmaceutical formulations |
| US12269813B2 (en) | 2019-02-22 | 2025-04-08 | Janssen Pharmaceutica Nv | Crystalline form of 1-(1-oxo-1,2-dihydroisoquinolin-5-yl)-5-(trifluoromethyl)-N-(2-(trifluoromethyl)pyridin-4-yl)-1H-pyrazole-4-carboxamide monohydrate |
| EP3953345B1 (fr) | 2019-04-11 | 2023-04-05 | Janssen Pharmaceutica NV | Dérivés de pyridines comme inhibiteurs de malt1 |
| US20210155990A1 (en) | 2019-11-22 | 2021-05-27 | Janssen Pharmaceutica Nv | Nf-kb regulated gene expression assay for assessing efficacy of malt1 inhibitors |
| KR20220116460A (ko) | 2019-11-22 | 2022-08-23 | 얀센 파마슈티카 엔.브이. | NF-kB 전좌 분석을 사용하여 MALT1 억제제의 효능을 평가하기 위한 방법 |
| WO2021138298A1 (fr) | 2019-12-30 | 2021-07-08 | Rheos Medicines, Inc. | Modulateurs de malt1 et leurs utilisations |
| TW202227067A (zh) | 2020-08-21 | 2022-07-16 | 比利時商健生藥品公司 | Ｍａｌｔ１抑制劑之無定形形式及其配製物 |
| JP2023538099A (ja) | 2020-08-21 | 2023-09-06 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｍａｌｔ１阻害剤と、ポリエチレングリコールの脂肪酸との混合物と、を含む、医薬製剤 |
| BR112023017689A2 (pt) | 2021-03-03 | 2023-11-14 | Janssen Pharmaceutica Nv | Método de tratamento de uma condição com o uso de uma dose terapeuticamente eficaz do inibidor de malt1 jnj-67856633 (1-(1-oxo-1,2-di-hidroisoquinolin-5-il)-5-(trifluorometil)-n(2-(trifluorometil)piridin-4-il)-1h-pirazol-4-carboxamida) |
| BR112023017648A2 (pt) | 2021-03-03 | 2023-11-14 | Janssen Pharmaceutica Nv | Terapia de combinação com o uso de um inibidor de malt1 e um inibidor de btk |
-
2020
- 2020-04-10 EP EP20717667.8A patent/EP3953345B1/fr active Active
- 2020-04-10 ES ES20717667T patent/ES2949871T3/es active Active
- 2020-04-10 JP JP2021559711A patent/JP7554768B2/ja active Active
- 2020-04-10 MX MX2021012417A patent/MX2021012417A/es unknown
- 2020-04-10 US US17/602,885 patent/US12404260B2/en active Active
- 2020-04-10 WO PCT/EP2020/060307 patent/WO2020208222A1/fr not_active Ceased
- 2020-04-10 AU AU2020272156A patent/AU2020272156A1/en not_active Abandoned
- 2020-04-10 MA MA055593A patent/MA55593A/fr unknown
- 2020-04-10 BR BR112021019799A patent/BR112021019799A2/pt not_active Application Discontinuation
- 2020-04-10 CN CN202080028070.1A patent/CN113677674B/zh active Active
- 2020-04-10 KR KR1020217036345A patent/KR20210151880A/ko not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022528919A (ja) | 2022-06-16 |
| KR20210151880A (ko) | 2021-12-14 |
| EP3953345B1 (fr) | 2023-04-05 |
| MX2021012417A (es) | 2021-11-12 |
| JP7554768B2 (ja) | 2024-09-20 |
| EP3953345A1 (fr) | 2022-02-16 |
| CN113677674B (zh) | 2024-08-23 |
| WO2020208222A1 (fr) | 2020-10-15 |
| US12404260B2 (en) | 2025-09-02 |
| CA3131856A1 (fr) | 2020-10-15 |
| US20220162187A1 (en) | 2022-05-26 |
| AU2020272156A1 (en) | 2021-10-14 |
| CN113677674A (zh) | 2021-11-19 |
| ES2949871T3 (es) | 2023-10-03 |
| BR112021019799A2 (pt) | 2021-12-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA55593A (fr) | Cycles pyridine contenant des dérivés servant d'inhibiteurs de malt1 | |
| MA54755A (fr) | Dérivés d'imidazo[1,2-a]pyridinyle servant d'inhibiteurs d'irak4 | |
| CY1122821T1 (el) | Παραγωγα 1,3-βενζοδιοξολιου ως αναστολεις εζη1 ή/και εζη2 | |
| MA56022A (fr) | Dérivés d'amino quinazoline servant d'inhibiteurs de p2x3 | |
| PH12020550786A1 (en) | Novel benzylamino substituted pyridopyrimidinones and derivatives as sos1 inhibitors | |
| AR106237A2 (es) | Inhibidores heterocíclicos de la aspartil proteasa, sus sales farmacéuticamente aceptables | |
| MA47125A (fr) | Dérivés de pyrazole en tant qu'inhibiteurs de malt1 | |
| MA49013A (fr) | Nouveaux dérivés hétérocycliques utiles en tant qu'inhibiteurs de shp2 | |
| GEAP202115066A (en) | BENZO[b]THIOPHENE COMPOUNDS AS STING AGONISTS | |
| SA518391307B1 (ar) | مركبات ومشتقات سبيرو [ إندول -3، 2- بيروليدين h3] أون جديدة على هيئة مثبطات الدقيقة المزدوجة للفأر(1h)2 بي2-53 | |
| MX2013007104A (es) | Derivados de biciclo[3,2,1]octilamida y sus usos. | |
| CR10359A (es) | Derivados de dihidropirazolopirimidinona | |
| GEAP202015169A (en) | Tyrosine amide derivatives as rho-kinase inhibitors | |
| BR112015018509A2 (pt) | compostos de imidazo piridina | |
| MA54411A (fr) | Compositions contenant de l'ibrutinib | |
| EP3941525A4 (fr) | Dérivés de benzodiazépine en tant qu'inhibiteurs de rsv | |
| EP3277381C0 (fr) | Dérivés de nitrobenzyle d'agents anticancéreux | |
| MA51431A (fr) | Dérivés d'oxy-fluoropipéridine utilisés en tant qu'inhibiteur de kinase | |
| PE20180412A1 (es) | Compuestos inhibidores de la senalizacion de la via de notch | |
| AR097894A1 (es) | Inhibidores terapéuticos de cdk8 o uso de los mismos | |
| EP3449001A4 (fr) | Inhibition de l'arnmi mir-22 par apt-110 | |
| EP4043450A4 (fr) | Dérivés 2h-benzopyrane utilisables en tant qu'inhibiteurs de crac | |
| MA50439A (fr) | Nouveaux dérivés de pyrazolo-pyrrolo-pyrimidine-dione utilisés en tant qu'inhibiteurs de p2x3 | |
| EP3946288A4 (fr) | Dérivés de 5-cyclopropyl-1h-pyrazol-3-yl-amine substitués utilisés en tant qu'inhibiteurs sélectifs de cdk12/13 | |
| EA201892264A1 (ru) | Производные тетрагидроизохинолина |